Literature DB >> 25711134

BSACI guideline for the management of chronic urticaria and angioedema.

R J Powell1, S C Leech, S Till, P A J Huber, S M Nasser, A T Clark.   

Abstract

This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is aimed at both adult physicians and paediatricians practising in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a Web-based system. Their comments and suggestions were carefully considered by the Standards of Care Committee. Where evidence was lacking, a consensus was reached by the experts on the committee. Included in this management guideline are clinical classification, aetiology, diagnosis, investigations, treatment guidance with special sections on children with urticaria and the use of antihistamines in women who are pregnant or breastfeeding. Finally, we have made recommendations for potential areas of future research.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  BSACI; IgE; Urticaria; adult; allergy; angioedema; anti-IgE; antihistamine; auto-antibody; autoimmune; breastfeeding; child; epidemiology; guideline; hypothyroidism; management; paraprotein; pregnancy

Mesh:

Year:  2015        PMID: 25711134     DOI: 10.1111/cea.12494

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  45 in total

Review 1.  Current and future therapies for the treatment of histamine-induced angioedema.

Authors:  Christine James; Jonathan A Bernstein
Journal:  Expert Opin Pharmacother       Date:  2017-01-25       Impact factor: 3.889

Review 2.  Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice.

Authors:  Paul V Williams
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

3.  Diet and Chronic Urticaria: Dietary Modification as a Treatment Strategy.

Authors:  Joanna Jaros; Vivian Y Shi; Rajani Katta
Journal:  Dermatol Pract Concept       Date:  2019-12-31

4.  Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on Treatment of Chronic Spontaneous Urticaria: A Randomized Controlled Study.

Authors:  Hiroyuki Murota; Hiroaki Azukizawa; Ichiro Katayama
Journal:  Chin J Integr Med       Date:  2017-08-17       Impact factor: 1.978

Review 5.  Antihistamines and allergy.

Authors:  Katrina L Randall; Carolyn A Hawkins
Journal:  Aust Prescr       Date:  2018-04-03

6.  Comparative Evaluation of the Therapeutic Efficacy and Safety of Injected Histaglobulin versus Autologous Serum Therapy in Chronic Urticaria.

Authors:  Sumir Kumar; Simranjeet Singh Dhillon; B K Brar; Amarbir Singh
Journal:  J Clin Aesthet Dermatol       Date:  2021-03-01

7.  Recommendations for the recognition, diagnosis, and management of long COVID.

Authors:  Huw Jenkins
Journal:  Br J Gen Pract       Date:  2022-05-26       Impact factor: 6.302

8.  Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria.

Authors:  Vippan Goyal; Anu Gupta; Onam Gupta; Dhruvendra Lal; Manharan Gill
Journal:  J Clin Diagn Res       Date:  2017-03-01

9.  Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes.

Authors:  Niklas Worm Andersson; Christian Torp-Pedersen; Jon Trærup Andersen
Journal:  JAMA Pediatr       Date:  2020-08-03       Impact factor: 16.193

Review 10.  The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; Maximiliano Gomez; Sandra Nora Gonzalez-Diaz; Bryan Martin; Mário Morais-Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-01       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.